Abstract

In the rapidly advancing field of pharmaceutical sciences, the quest for innovative therapeutics to address complex diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis has brought structureactivity relationship (SAR) analysis into sharp focus. SAR analysis serves as a cornerstone for medicinal chemistry and drug discovery, bridging the gap between molecular design and biological function. While SAR-guided development often culminates in therapeutic breakthroughs, it also yields chemical tools that, though not immediately translatable to clinical settings, provide critical insights into disease mechanisms and inspire subsequent research endeavours.